Assessment of dimethylxanthine formation from caffeine in healthy adults: Comparison between plasma and saliva concentrations and urinary excretion of metabolites

References

• Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theo-bromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73–7
   PubMedGoogle Scholar
• Fuhr U, Doehmer J, Battula N, Wölfel C, Flick I, Kudla C, et al. Biotransformation of methylxan-thines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones. Toxicology 1993; 82: 169–89
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Anderson T, et al. Caffeine metabolism by human hepatic cytochromes P450: contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767–76
   PubMed Web of Science ®Google Scholar
• Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearance in man. Br J Clin Pharmacol 1986; 22: 183–6
   PubMed Web of Science ®Google Scholar
• Carrier O, Pons G, Rey E, Richard MO, Moran C, Badoual J, et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 1988; 44: 145–51
   PubMed Web of Science ®Google Scholar
• Lelo A, Birkett DJ, Robson A, Miners JO. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 1986; 22: 177–82
   PubMed Web of Science ®Google Scholar
• Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982; 32: 98–106
   PubMed Web of Science ®Google Scholar
• Tang-Liu D-S, Williams RL, Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 1983; 224: 180–5
   PubMed Web of Science ®Google Scholar
• Lelo A, Miners JO, Robson R, Birkett DJ. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther 1986; 39: 54–9
   PubMed Web of Science ®Google Scholar
• Callahan MM, Robertson RS, Branfman AR, McComish MF, Yesair DW. Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. Drug Metab Dispos 1983; 11: 211–7
   PubMed Web of Science ®Google Scholar
• Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Phar Ther 1987; 42: 157–65
   PubMed Web of Science ®Google Scholar
• Rodopoulos N, Widn O, Norman A. Caffeine metabolism in patients with chronic liver disease. Scand J Clin Lab Invest 1995; 55: 229–42
   PubMed Web of Science ®Google Scholar
• Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503–14
   PubMed Web of Science ®Google Scholar
• Tanaka E, Ishikawa A, Yamamoto Y, Osada A, Tsuji K, Fukao K, et al. A simple useful method for determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. Int J Clin Pharmacol Ther Toxicol 1992; 30: 336–41
   PubMed Web of Science ®Google Scholar
• Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthtne/caffeine ratio in plasma and saliva. Pharmacogenetics 1994; 4: 109–16
   PubMedGoogle Scholar
• Tang B-K, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648–57
   PubMed Web of Science ®Google Scholar
• Relling M, Lin J-S, Ayers G, Evans W. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643–58
   PubMed Web of Science ®Google Scholar
• Carrillo J, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator pheno-type and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293–304
   PubMed Web of Science ®Google Scholar
• Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402–11
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar F, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Canc Epidemiol Biom Prevent 1994; 3: 413–21
   PubMed Web of Science ®Google Scholar
• Tang B-K, Zhou Y, Kadar D, Kalow W. Caffeine as a pobe for CYP1A2 activity: potencial influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117–24
   PubMedGoogle Scholar
• Vincent-Viry M, Braz Vieira da Silva Pontes Z, Gueguen R, Galtteau M-M, Siest G. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acety-lation phenotypes. Genet Epidemiol 1994; 11: 115–29
   Google Scholar
• Rodopoulos N, Norman A. Determination of caffeine and its metabolites in urine by high-performance liquid chromatography and capillary electrophoresis. Scand J Clin Lab Invest 1994; 54: 305–15
   PubMed Web of Science ®Google Scholar
• Muir KT, Kunitani M, Fiegelman S. Improved high-performance liquid chromatographic assay for theophylline in ph and saliva in the presence of caffeine and its metabolites and comparisons with three other assays. J Chromatogr 1982; 231: 73–82
   PubMed Web of Science ®Google Scholar
• Callahan MM, Robertson RS, Amaud MJ, Branfman AR, McComish MF, Yesair DW. Human metabolism of [1-methyl-14C]- and [2–14C]caffeine after oral administration. Drug Metab Dispos 1982; 10: 417–23
   PubMed Web of Science ®Google Scholar
• Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clin Pharmacokinet 1978; 3: 39–57
   PubMed Web of Science ®Google Scholar
• Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992; 23: 365–79
   PubMed Web of Science ®Google Scholar
• Gorodischer R, Koren G. salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoriong. Dev Pharmacol Ther 1992; 19: 161–77
   PubMedGoogle Scholar
• Zylber-Katz E, Granit L, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin pharmacol Ther 1984; 36: 133–7
   PubMed Web of Science ®Google Scholar